CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria: The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF)（For minors, the guardian shall also provide written informed consent ）; Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease; Age 14-60 years; ECOG score: ≤2; Relapsed/refractory AML must meet one of the following conditions: Twice or more relapse; Newly diagnosed AML patients who failed after 2 cycles of standard chemotherapy; Relapse within 12 months after CR, or relapse after 12 months with CR but failed to respond to conventional chemotherapy; Persistent extramedullary leukemia. Meet the requirements of allogeneic HSCT Expected survival ≥ 3 months; Exclusion Criteria: Subject with APL/AML-M3:t(15;17)(q22;q12) Received any of the following treatments: Previous allo-HSCT(Subjects who received allo-HSCT for more than 6 months, have stopped immunosuppressive drugs and have no active GvHD are not included in the exclusion criteria) Previous gene therapy Previous anti CD33/CLL1 therapy Previous any target CAR-T cells therapy Prior antitumor therapy with insufficient washout period; CNS infiltration; Except for patients with prior CNS infiltration who are currently in remission; HBsAg, HBV DNA, HCV-Ab, HCV RNA or HIV-Ab positive; Pregnant or breast-feeding women;